References
- Maciel G, Crowson CS, Matteson EL, Cornec D. Prevalence of primary Sjogren’s syndrome in a us population-based cohort. Arthritis Care Res. 2017;69(10):1612–1616. doi:10.1002/acr.23173
- Fox RI. Sjogren’s syndrome. Lancet. 2005;366(9482):321–331. doi:10.1016/S0140-6736(05)66990-5
- Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med. 2004;164(12):1275–1284. doi:10.1001/archinte.164.12.1275
- Kruszka P, O’Brian RJ. Diagnosis and management of Sjogren syndrome. Am Fam Physician. 2009;79(6):465–470.
- Manthrope R, Asmussen K, Oxholm P. Primary Sjogren’s syndrome: diagnostic criteria, clinical features, and disease activity. J Rheumatol Suppl. 1997;50:8–11.
- Pattar GR, Jerkins G, Evans DG, et al. Symptom improvement in dry eye subjects following intranasal tear neurostimulation: results of two studies utilizing a controlled adverse environment. Ocul Surf. 2020;18(2):249–257. doi:10.1016/j.jtos.2019.09.006
- Sheppard JD, Torkildsen GL, Geffin JA, et al. Characterization of tear production in subjects with dry eye disease during intranasal tear neurostimulation: results from two pivotal clinical trials. Ocul Surf. 2019;17(1):142–150. doi:10.1016/j.jtos.2018.11.009
- Gizurarson S. Anatomical and histological factors affecting intranasal drug and vaccine delivery. Curr Drug Deliv. 2012;9(6):566–582. doi:10.2174/156720112803529828
- Dieckmann G, Fregni F, Hamrah P. Neurostimulation in dry eye disease-past, present, and future. Ocul Surf. 2019;17(1):20–27. doi:10.1016/j.jtos.2018.11.002
- Friedman NJ, Butron K, Robledo N, et al. A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease. Clin Ophthalmol. 2016;10:795–804.
- Cohn GS, Corbett D, Tenen A, et al. Randomized, controlled, double-masked, multicenter, pilot study evaluating safety and efficacy of intranasal neurostimulation for dry eye disease. Invest Ophthalmol Vis Sci. 2019;60(1):147–153. doi:10.1167/iovs.18-23984
- Gumus K, Schuetzle KL, Pflugfelder SC. Randomized controlled crossover trial comparing the impact of sham or intranasal tear neurostimulation on conjunctival goblet cell degranulation. Am J Ophthalmol. 2017;177:159–168. doi:10.1016/j.ajo.2017.03.002
- Pondelis N, Dieckmann GM, Jamali A, et al. Infrared meibography allows detection of dimensional changes in meibomian glands following intranasal neurostimulation. Ocul Surf. 2020;18(3):511–516. doi:10.1016/j.jtos.2020.03.003
- Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9–16. doi:10.1136/annrheumdis-2016-210571
- Farhangi M, Cheng AM, Baksh B, et al. Effect of non-invasive intranasal neurostimulation on tear volume, dryness and ocular pain. Br J Ophthalmol. 2020;104(9):1310–1316.